Last reviewed · How we verify

NCT06580249

Efficacy and Mechanism of rTMS on the Symptoms of Pleasure Deficit in Adolescent Depression

Recruiting now NA Last updated 23 September 2024
What this trial tests

NA trial testing Repetitive transcranial magnetic stimulation in Depression in 44 participants. Currently enrolling.

Timeline
5 September 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorXijing Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment44
Start date5 September 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

Adults 10 to 19, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

(1) Primary objective: to collect data on the score of pleasure deficit scale before and after repetitive transcranial magnetic stimulation treatment in adolescent depressed patients, and to verify its efficacy and safety in adolescent depressed patients in combination with the changes of clinical symptoms; (2) Secondary objective: to explore the relevant hemodynamic mechanisms in adolescent depressed patients before and after repetitive transcranial magnetic stimulation treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Repetitive transcranial magnetic stimulation

Trials testing the same drug.

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06580249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing